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The peptidylarginine deiminases (PADs) are a family of posttranslational modification enzymes that catalyze the conversion of
positively charged protein-bound arginine and methylarginine residues to the uncharged, nonstandard amino acid citrulline. This
enzymatic activity is referred to as citrullination or, alternatively, deimination. Citrullination can significantly aﬀect biochemical
pathways by altering the structure and function of target proteins. Five mammalian PAD family members (PADs 1–4 and 6) have
been described and show tissue-specific distribution. Recent reviews on PADs have focused on their role in autoimmune diseases.
Here, we will discuss the potential role of PADs in tumor progression and tumor-associated inflammation. In the context of cancer,
increasing clinical evidence suggests that PAD4 (and possibly PAD2) has important roles in tumor progression. The link between
PADs and cancer is strengthened by recent findings showing that treatment of cell lines and mice with PAD inhibitors significantly
suppresses tumor growth and, interestingly, inflammatory symptoms. At the molecular level, transcription factors, coregulators,
and histones are functional targets for citrullination by PADs, and citrullination of these targets can aﬀect gene expression in
multiple tumor cell lines. Next generation isozyme-specific PAD inhibitors may have therapeutic potential to regulate both the
inflammatory tumor microenvironment and tumor cell growth.
1. Introduction
PAD-mediated citrullination can alter the tertiary structure
of target substrates and/or alter protein-protein interactions;
thus aﬀecting various cellular processes [1, 2] (Figure 1).
Recently, protein citrullination has garnered increased atten-
tion due to its role in the pathogenesis of various inflamma-
tory conditions such as rheumatoid arthritis (RA), multiple
sclerosis, psoriasis, chronic obstructive pulmonary disease
(COPD), neurodegenerative diseases and, also, due to its
emerging role in various human and animal cancers [3–7].
In this paper, we will first briefly discuss the tissue-specificity
and hormonal regulation of the five PAD isoforms and
then focus on the potential role of this enzyme family in
carcinogenesis, tumor progression, and inflammation.
2. Tissue Expression Patterns and Substrate
Specificity of PAD Family Members
PADs are Ca2+-dependent enzymes and there are five
diﬀerent isozymes in mammals, namely, PAD1, 2, 3, 4, and
6 [8, 9]. The PAD genes likely arose by duplication of the
ancestral homologue, PAD2, and are localized to a well-
organized gene cluster at 1p36.13 in humans. Interestingly,
this locus is also predicted to contain a novel, yet to be
defined, tumor suppressor protein [10]. PAD enzymes are
highly homologous, with ∼50–60 percent sequence identity
at the amino acid level. Although there is some overlap with
respect to target proteins, each family member also appears
to target a unique set of cellular proteins as well [11, 12].
Additionally, as described below, each family member also
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Figure 1: Peptidylarginine deiminase (PAD) enzymes catalyze the conversion of protein arginine residues to citrulline.
exhibits a tissue-selective distribution pattern. We note here
that, in this paper, we will be using the more commonly
utilized gene synonym, PAD, while the approved HUGO
Gene Nomenclature Committee gene names for the family
members are actually PADI1, PADI2, PADI3, PADI4, and
PADI6.
PAD1 appears to primarily be expressed in the epidermis
and uterus. In the epidermis, PAD1 citrullinated cytokeratin
and this modification is important for modulating the
cornification of the epidermis and maintaining the barrier
function of superficial keratinized epidermal cell layers.
The loss of charge following citrullination of cytokeratin
causes disassembly of the cytokeratin-filaggrin complex and
proteolytic degradation of these targets.
PAD2 is expressed in multiple organs, including the
brain, female reproductive tissues, skeletal muscle, and cells
of the hematopoietic lineage. In the brain, a major target for
PAD2 is myelin basic protein (MBP), a constituent of the
myelin sheath [13, 14]. Citrullination of MBP by PAD2 likely
plays a key role in the pathogenesis of neurodegenerative
disease [15]. PAD2 can also citrullinate the intermediate fil-
ament vimentin in macrophages [16], leading to cytoskeletal
disintegration and eventually apoptosis. In female repro-
ductive tissues, PAD2 levels appear to be regulated by
hormones, predominantly estrogen, and also possibly by
epidermal growth factor [17]. PAD2 has also been found to
be expressed in human mammary gland epithelial cells, with
a fraction of PAD2 in these cells localizing to the nucleus
and binding directly to chromatin [18]. In canine mammary
tissue, histone citrullination levels closely correlate with the
expression of PAD2 across the estrous cycle, suggesting that
PAD2 may target histones for citrullination in this tissue
[17]. In support of this prediction, a recent study has found
that PAD2-catalyzed citrullination of histone H3 arginine 26
can regulate estrogen receptor α target gene activity [19].
PAD3 expression is highly restricted to the hair follicle
and epithelium and a major target for PAD3 is trichohyaline.
Additionally PAD3 can also citrullinate filaggrin leading to
altered epidermal homeostasis and loss of barrier function
[20].
PAD4 is expressed in hematopoietic progenitor cells,
immune cells such as granulocytes, monocytes and
macrophages, natural killer cells, and carcinoma cells
originating from lung, esophagus, breast, and ovary [5, 21].
PAD4 is often localized to the nucleus and is the only
PAD family member with a canonical nuclear localization
sequence [22]. Antithrombin has been found to be an
extracellular PAD4 substrate [23] and citrullination of this
target suppresses the ability of antithrombin to inhibit
thrombin [24]. Increased thrombin activity is considered to
be a hallmark of cancer by promoting angiogenesis, increased
tumor growth, and distant metastasis. Interestingly,
citrullinated antithrombin levels are elevated in serum
samples from patients with malignant cancers, thus raising
the possibility that PADs may aﬀect tumor progression via
citrullination of antithrombin [25].
PAD4 also appears to function as a transcriptional
coregulator for a range of factors such as p53, ELK1, p300,
p21, CIP1, nucleophosmin, and ING4 [26–30]. While the
mechanism by which PAD4 regulates target gene activity is
not entirely clear, Edman degradation and analysis using site-
specific anticitrullinated histone antibodies has found that
PAD4 can target the N-terminal tails of histones H2A, H3,
and H4 for citrullination. More specifically, PAD4 has been
found to directly citrullinate histone H4 and H2A at arginine
3, and histone H3 at arginines’ 2, 8, 17, and 26. Histone
tail citrullination has been found to promote chromatin
decondensation in vitro and in vivo [31, 32]. Thus, it seems
likely that the gene regulatory role of PAD4 is mediated by
its initial recruitment to target promoters by the relevant
transcription factor, followed by subsequent deimination of
specific residues in the N-terminal histone tails, leading to
local changes in chromatin architecture and modulation of
target gene expression (Figure 2). PAD4 is both a corepressor
and coactivator of gene transcription and also appears to
contribute to epigenetic cross-talk [33] during DNA damage
by acting in concert with histone deacetylase 2 (HDAC2)
to regulate p53 target gene activity [34]. Following DNA
damage, PAD4 and HDAC2 separate from the p53-target
gene promoters such as p21, GADD45, and PUMA, resulting
in an increased incidence of histone Lys acetylation and Arg
methylation at these sites.
PAD6 is a maternal eﬀect gene that is specifically
expressed in oocytes and preimplantation embryos and
is essential for embryonic development beyond the 2-cell
stage [35]. To date, there has been little evidence that this
ovarian PAD isozyme is involved in cancer. Interestingly,
however, a genome-wide SNP association in Icelanders
showed a significant correlation between cutaneous-basal
cell carcinoma risk and mutations in the PAD4/PAD6 locus
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Figure 2: PAD-mediated histone tail citrullination leads to chromatin decondensation.
at 1p36 [36]. The importance of this PAD family member
in developmental biology is reviewed elsewhere [37, 38] and
will not be discussed further in this paper.
3. Hormonal Regulation of PADs
Early PAD biological studies focused mainly on the expres-
sion patterns of the diﬀerent family members in reproductive
tissues and also on their catalytic activity at these sites.
Outcomes from these studies showed that anterior pituitary-
localized rat lactotroph cells express PAD2 in a sexually
dimorphic fashion, with expression confined to the female.
Additional studies showed that PADs 1, 2, and 4 are present
in uterine tissue and that protein citrullination is extensive in
the uterine epithelium in an estrus cycle-dependent manner
[39, 40]. More recently, studies have found that mouse, dog,
and human mammary glands express both PAD2 and 4 in
luminal epithelial cells [17].
3.1. Pituitary Gland and Uterus. In the female rat pituitary,
PAD enzymatic activity is highest during proestrus and
estrus when serum estrogen levels are at their peak [39, 41].
Ovariectomy of rats suppressed PAD activity in pituitary
lysates, but activity could be restored by injection of exoge-
nous estrogen. Furthermore, treatment of the pituitary-
derived MtT/S cell line with estrogen results in a dose-
dependent increase in PAD expression and activity [42].
Together, these observations suggest that estrogen directly
influences PAD expression and activity in the pituitary. Given
that estrogen primes lactotrophs for prolactin biosynthesis,
PAD enzymatic activity may play an important role in this
normal physiological process andmay also promote pituitary
neoplastic growth.
Our examination of Massively Parallel Signature
Sequencing (MPSS) transcriptome data (GEO Profiles
GDS868) indicates that PADs 1, 2, and 4 expression levels
are highest in the mouse uterus as compared to the 50
other tissues examined [43]. Furthermore, analysis of cDNA
microarray data from Hewitt et al. shows that PAD1, 2, and
4 mRNA appear to be estrogen regulated [44]. In the uterus,
the distribution of these isozymes appears to be primarily
limited to glandular and luminal epithelial cells and also
displays an estrous cycle-dependent regulation pattern, with
the highest expression of these family members occurring
during estrus [45, 46]. Similar to the pituitary, PAD2 and
PAD4 expression and activity in the uterus is lost following
ovariectomy, but can be restored by injection of exogenous
estrogen, indicative of estrogen regulation [45, 46]. Given
the known mitogenic properties of estrogen in female
cancers, it is possible that estrogen-induced upregulation
of PAD expression and activity in the uterus may promote
neoplastic growth in this tissue. However, a potential role for
PADs in pituitary and uterine tumor progression has yet to
be investigated.
3.2. Mammary Gland. Protein andmRNA expression studies
in canine mammary glands collected at various stages
of the estrous cycle show that PAD2 expression initiates
during estrus, with mRNA and protein levels peaking
during diestrus. In the mouse mammary gland PAD2 and
4 expression is highest in luminal epithelial cell populations
during the estrus [17, 46]. This species-specific diﬀerence in
expression levels may reflect diﬀerences in estrous cycle stage
lengths and hormone levels between species. Ovariectomy
in mice also results in loss of PAD2 and 4 expression
in the mammary gland, thus further corroborating the
role of estrogen in PAD expression in female reproductive
tissues. Molecular studies show that treatment of MCF-
7 cells with estrogen rapidly induced the upregulation of
PAD4 and the involvement of estrogen in PAD4 expression
in mammary epithelial cells appears to be mediated by two
upstream estrogen response elements (designated ERE −125
and −126) which are bound by ERα following estrogen
treatment. Furthermore, this study showed that the ERα-
dependent increase in PAD4 expression can also be mediated
by estrogen signaling to the PAD4 proximal promoter via
cross-talk with the AP-1, Sp-1, and NF-Y transcription
factors [47].
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Figure 3: H4cit3 immunostaining of DCIS xenograft sections. Dotted line demarcates the area adjacent to the central necrotic core of the
comedo-DCIS lesion. (Magnification 400x).
4. PAD4-Mediated Histone Tail
Citrullination: An Emerging Role for
PADs in Gene Regulation and Cancer
PAD4 has also been found to regulate estrogen receptor target
gene activity following estrogen stimulation via histone tail
citrullination [48]. Given the role of estrogen as a mitogen
in cancer cells, this observation provides a clear potential
link between PAD activity and cancer growth. In addition to
estrogen, another mitogen, EGF, has been shown to utilize
PAD4 as a cofactor to activate target gene activity. Zhang et
al. documented that treatment ofMCF-7 cells with EGF leads
to PAD4-mediated citrullination of the ELK1 oncogene. This
citrullination event then facilitated subsequent phosphoryla-
tion of ELK1 by ERK1/2, which, in turn, promoted histone
acetylation and subsequent activation of a range of targets
including the immediate early gene, c-fos [30].
PAD4 has also been found to interact with the major
tumor suppressor, p53, and aﬀect the expression of p53
target genes such as p21, OKL38, CIP1, and WAF1 [26–
30]. Interestingly, a recent study also found that citrullina-
tion levels at histone H4 arginine 3 (H4R3) are inversely
correlated with p53 protein expression and with tumor
size in nonsmall cell lung cancer tissues [32]. The authors
also demonstrated that the p53-PAD4 pathway leads to
citrullination of H4R3 and Lamin C in response to DNA
damage and nuclear fragmentation. They also found that
PAD4-mediated H4R3 citrullination appears to lead to
localized chromatin decondensation around sites of DNA
damage, thus facilitating p53-mediated cell death. In vivo
studies then demonstrated that even though PAD4-null mice
were grossly normal with regard to organmorphologies, they
appeared resistant to apoptotic stimuli and also showed a
consistent reduction in cleaved caspase-3 expression. The
authors conclude that the histone H4 citrulline 3 (H4Cit3)
modification may form a novel “apoptotic code” which
could potentially be used to detect a range of damaged
cells, including tumor cells, following treatment of patients
with cancer therapies. It is interesting to note, however, that
the PAD inhibitor Cl-amidine increases p53 levels both in
cell culture and in inflammatory cells isolated from mice
treated with this compound [29, 49]. Reconciling these two
disparate observations requires further study. In support of
a role for the H4Cit3 modification in marking apoptotic
tumor cells, recent immunofluorescence studies in our lab
found that citrullination at H4R3 was very robust within the
nucleus of epithelial cells undergoing morphological changes
associated with various stages of apoptosis in comedo-
DCIS xenograft sections (Figure 3). These xenografts were
generated from MCF10DCIS cell line which belongs to the
group of MCF10AT tumor progression series of cell lines
[50, 51].
From a more clinical perspective, recent immunohisto-
chemical and western blot studies have found that PAD4
appears to be overexpressed in several types of invasive
carcinomas [5, 52, 53]. Outcomes from these studies found
that PAD4 expression and, frequently activity, was elevated in
neoplastic cells from breast carcinomas, lung adenocarcino-
mas, hepatocellular carcinomas, esophageal carcinomas with
squamous diﬀerentiation, colorectal adenocarcinomas, renal
carcinomas, ovarian adenocarcinomas, uterine carcinomas,
uterine adenocarcinomas, and bladder carcinomas [52].
However, PAD4 expression was absent or minimal in the
following tumors: benign gastric and uterine leiomyomas,
hyperplastic conditions of endometrium, cervical polyps,
teratomas, hydatidiform moles, hemangiomas, lymphatic
proliferative conditions, schwannomas, and neurofibromas
[5]. Consistent with the PAD4 protein expression pattern in
carcinomas, the same patients also had elevated serum PAD4
activity and citrullinated antithrombin levels. Taken together,
these observations support the potential use of this enzyme
as a clinical prognostic biomarker.
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Figure 4: PAD2 IHC staining of the normal human mammary gland, a DCIS lesion, and invasive carcinomas. Nuclear staining intensity is
reduced in most invasive tumors while a subset of these tumors retains strong PAD2 staining. (Magnification 200x).
DCIS Invasive Metastatic
Figure 5: PAD2 (green) is expressed in luminal epithelial cells of preinvasive, invasive, andmetastatic humanmammary tumors. Cytokeratin
(red) staining diﬀerentiates luminal epithelial type from myoepithelial cells. (Magnification 400x).
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Figure 6: PAD inhibitors and their selectivity (TDFA-Threonine-aspartate-F-amidine; TDCA-Threonine-aspartate-Cl-amidine).
5. PAD2 and Cancer Pathogenesis
Given the volume of recent literature linking PAD4 with
gene regulation in cancer cells, a role for this family member
in tumor progression seems likely. Comparative studies
evaluating PAD2 expression in mammary carcinomas from
humans, dogs, and cats show that the nuclear localization
of PAD2 may also prove to be associated with tumor
progression. Normal human, canine, and feline mammary
tissue shows strong nuclear and cytoplasmic PAD2 staining,
but as tumors progress there is a general reduction in the
nuclear localization of PAD2 (Figures 4 and 5) [54]. In the
mammary gland, PAD2 expression is specific to cytokeratin
positive luminal type epithelial cells (Figure 5). Thus, the loss
of nuclear PAD2 may result in alterations in gene expression
that lead to neoplastic transformation. It is interesting to note
that a subset of invasive breast carcinomas tend to retain
strong cytoplasmic and nuclear expression of PAD2. Further
characterization of this subclass of tumors with regard to
function of PAD2 is warranted as isozyme specific PAD
inhibitors may be of use in combinatorial therapies to treat
such tumor types.
Given these new findings, and PAD4’s documented role
in cancer biology, it will be interesting to determine whether
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Figure 7: Potential role of PAD enzymes in cancer pathogenesis.
PAD2 and PAD4 may function in a synergistic manner
to promote tumor progression. The observation that both
PAD2 and PAD4 expression appears to be regulated at some
level by estrogen, suggests that these two PADs may work
together to mediate the estrogen response. The observations
that PAD2 expression in mammary epithelial cells is induced
by EGF [17], and that PAD4 regulates EGF-induced ELK1
target gene activation, suggests that PAD2 and PAD4 may
also cooperate to mediate EGFR signaling [30].
6. PAD Inhibitors Block Cancer Progression
In further support of a role for PADs in tumor growth,
several recent reports have also shown that treatment of
cancer cell lines with PAD inhibitors decreases cancer cell
viability without aﬀecting the growth of normal cells [55].
Cl-amidine [56], and the related PAD4 inhibitor, F-amidine
[57], display low micromolar cytotoxicity towards various
tumor cell lines such as U2OS cells, HL-60, HT-29, and
MCF-7 [29, 55, 58]. These compounds also can induce the
diﬀerentiation of HL-60 cells, a leukemic cell line, making
these cells more susceptible to drug treatments [55]. Cl-
amidine can also act synergistically with the anticancer drug
doxorubicin, thus enhancing the eﬃciency of cell death fol-
lowing a simultaneous treatment with these two compounds.
In tumor, cell lines such as MCF-7 cells, Cl-amidine also
regulates the expression of the tumor suppressor protein
OKL38 in a p53-dependent manner by decreasing histone
citrullination at the OKL38 promoter [28, 29].
A recent study, using a Cl-amidine derivative with
increased cell permeability, YW3-56 (Figure 6), found that
this drug significantly suppressed cancer cell growth and
also reduced tumor size in mouse xenograft models of
sarcoma [59]. Furthermore, this compound aﬀected the
expression of genes related to cell proliferation and cell
death and was also found to regulate macro-autophagy in
cancer cells. Mechanistically, the authors discovered that the
drug likely targeted factors within the mTORC1 pathway
for inhibition. These studies, as well as the demonstration
that PAD inhibitors are well tolerated in multiple diﬀerent
mouse disease models [49, 60], underscores the potential of
PAD inhibitors as novel epigenetic anticancer drugs. Given
that Cl-amidine, F-amidine, and YW3-56 display limited
selectivity (Figure 6), it is unclear whether the inhibition
of one or more PADs is required for the in vivo eﬀects of
these compounds. The development of new, more selective
compounds, such as the PAD4 selective inhibitor TDFA and
the PAD1 selective inhibitor o-F-amidine (Figure 6), will
undoubtedly prove to be useful for sorting this issue out.
7. PAD-Mediated Citrullination: Linking
Inflammation with Cancer Progression?
7.1. Role of Inflammation in Cancer Progression. Chronic
inflammation is involved in the progression and recur-
rence of many types of cancer, including breast cancer.
Epidemiological studies have documented that high levels of
circulating acute phase inflammation-associated proteins at
3 years after-treatment are associated with an elevated risk
for subsequent tumor recurrence and mortality in women
[61]. Several studies have also demonstrated direct links
between circulating inflammatory markers and progression
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to metastatic breast cancer [62–66]. Additionally, proin-
flammatory cytokines are well known for promoting tumor
growth and facilitating metastasis by altering the tumor
cell phenotype and by regulating stromal cells (endothelial
cells, tumor-associated macrophages, and fibroblasts) within
the tumor microenvironment. Furthermore, infiltrating
immune cells within the tumor itself can promote tumori-
genesis [67]. These findings suggest that the mechanisms
by which inflammation in the tumor microenvironment
drives metastasis is both intimately linked and fundamentally
diﬀerent to the primary mechanisms driving carcinogenesis
[68].
7.2. Role of PADs in Inflammation. As noted earlier, numer-
ous studies have documented increased protein citrullination
within inflamed tissues from patients with autoimmune
diseases such as rheumatoid arthritis and colitis [3, 4, 69].
More recently, these inflammatory symptoms have been
shown to be suppressed by the PAD inhibitor, Cl-amidine,
in mouse models of colitis and RA [49]. Another emerging
link between PADs and inflammation is the newly defined
role for PAD4 in catalyzing histone hypercitrullination
during Neutrophil Extracellular Trap (NET) formation in
inflamed tissues. A number of recent reports have shown
that, following activation, peripheral blood neutrophils
form a highly decondensed chromatin structure that both
captures and kills invading pathogens [70–72]. Mechanisti-
cally, PAD4 was found to catalyze this dramatic chromatin
decondensation event via histone tail hypercitrullination
[73]. Analysis of this process at the ultrastructural level by
electron microscopy showed that, following PAD4 activation
in HL60 granulocytes, these cells show a dramatic and rapid
conversion of multilobular heterochromatic nuclei to a more
round euchromatic nuclear architecture, suggesting a direct
role for PADs in heterochromatic-euchromatic interchange
[31]. These new findings indicate that PAD4 can mediate
chromatin structure change both at the local and genome-
wide level.
Citrullination of vimentin is correlated with the prolif-
eration of fibroblast-like synoviocytes (following isolation
from patients with rheumatoid arthritis) and also stimulates
TNF-α and IL-1 production in these cells [74]. Given the
links between vimentin citrullination, inflammation, and cell
proliferation, and given how important cytoskeletal integrity
is for cell motility, we hypothesize that citrullination of
vimentin by PAD enzymes may also aﬀect tumor cell migra-
tion and promote an inflammatory microenvironment.
Additionally, given that PAD2 can regulate cytokine signaling
in macrophages via citrullination of IKKγ (thus suppress-
ing NF-kB activity) [75], we predict that PAD-mediated
regulation of macrophage activity could also potentially
aﬀect cross-talk between tumor-associated macrophages and
cancer cells.
While PAD activity has primarily been found to regulate
autoimmune-mediated inflammatory events, recent studies
suggest that PAD-mediated citrullination is also elevated
in a variety of inflammatory states which lack a strong
autoimmune component, such as COPD and myositis [76–
78]. Perhaps the best demonstration that PAD-mediated
citrullination can facilitate nonautoimmune or microbial-
induced inflammatory events is the recent finding that PAD
activity is strongly upregulated in inflamed tissue following a
sterile skin punch biopsy procedure in mice [79]. Thus, it can
be inferred that PAD-mediated citrullination plays a critical
and fundamental role in inflammatory events induced by a
range of pathologies, both infectious and noninfectious.
7.3. Role of PADs in Chemokine Signaling. PAD2 and PAD4
are highly expressed in peripheral blood mononuclear cells
such as NK cells, T cells, B cells, and monocytes [16]
and, thus, are likely to be the main PAD “players” in
chemokine signaling. Chemokines are important for the
proper recruitment of leukocytes to the site of inflamma-
tion. The chemokine-receptor system can be dramatically
modified in neoplasms, especially at the invasive edges,
and can act as a proangiogenic and a prodesmoplastic
mediator. Several chemokines, including CXCL1, 2, and 8
have been found to exert eﬀects on tumor cell growth.
The CXC group of chemokines, with the tripeptide (Glu-
Leu-Arg/ELR) at the amino-terminus of the CXC motif
(ELR+), is proangiogenic and stimulates cell migration
and proliferation. The capacity of chemokines to activate
or repress biological pathways depends, in part, upon
posttranslational modifications such as glycosylation and
on proteolytic processing of the chemokine’s N- or C-
terminus [80]. Importantly, PADs have recently been found
to citrullinate CXCL5, CXCL8, CCL17, and CCL26 [81], thus
directly modulating the inflammatory milieu. Furthermore,
chemokine citrullination does not appear to be a rare event
in vivo, as, for example, CXCL8 was found to be citrullinated
at arginine 5 in 14% of all blood leukocyte derived CXCL8
[81]. While the role of citrullinated chemokines in the
inflammatory process is currently coming to light, their eﬀect
in cancer progression has yet to be investigated. However,
given the strong links between inflammation and cancer
progression, these observations support the hypothesis that
PAD activity may play an important role in regulating the
inflammatory milieu of the cancer microenvironment.
8. Conclusions
Protein citrullination is emerging as a critical posttransla-
tional modification in developmental biology, inflammation,
and cancer pathogenesis. With respect to cancer, PAD
enzymes are now being identified as important potential
players in tumor progression that both regulate transcrip-
tional activity and modulate the inflammatory microenvi-
ronment via cytokine citrullination. The major likely roles
of PADs in cancer pathogenesis are summarized in Figure 7.
Given these emerging links between PADs and cancer biol-
ogy, a better understanding of the upstreammechanisms that
induce PAD expression, and the downstream mechanisms
by which PADs regulate gene expression and inflammatory
events will likely advance our understanding of tumor
biology. Furthermore, the upregulation of specific PAD
isozymes and activity at critical points of tumor progression
raises the possibility that these enzymes, and their resulting
Biochemistry Research International 9
posttranslational modifications, can function as novel cancer
biomarkers. Lastly, the observations that (1) PAD inhibitors
reduce inflammatory symptoms in mouse models of disease,
(2) the link between PADs, inflammation, and cancer
is currently unfolding, and (3) next generation isozyme-
specific PAD inhibitors are currently being developed, raise
the possibility that the use of PAD inhibitors in preclinical
and clinical cancer therapies may soon be realized.
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